It has been also described that NF-κB activation in glioblastoma cells by RSL3 treatment leads to an increase of lipid ROS and a reduction of anti-ferroptosis proteins such as GPX4, ATF4, and SLC7A11 [342]. This evidence concerns the gene ATF4 and glioblastoma.